JP2012236849A5 - - Google Patents

Download PDF

Info

Publication number
JP2012236849A5
JP2012236849A5 JP2012174860A JP2012174860A JP2012236849A5 JP 2012236849 A5 JP2012236849 A5 JP 2012236849A5 JP 2012174860 A JP2012174860 A JP 2012174860A JP 2012174860 A JP2012174860 A JP 2012174860A JP 2012236849 A5 JP2012236849 A5 JP 2012236849A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
medicament
glp
composition according
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012174860A
Other languages
English (en)
Other versions
JP2012236849A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012174860A priority Critical patent/JP2012236849A/ja
Priority claimed from JP2012174860A external-priority patent/JP2012236849A/ja
Publication of JP2012236849A publication Critical patent/JP2012236849A/ja
Publication of JP2012236849A5 publication Critical patent/JP2012236849A5/ja
Pending legal-status Critical Current

Links

Claims (17)

  1. ジペプチジルペプチダーゼ４阻害化合物とＧＬＰ−１分泌促進作用を有する非糖質系甘味料とを組み合わせてなる医薬組成物。
  2. ジペプチジルペプチダーゼ４阻害化合物を含有してなり、ＧＬＰ−１分泌促進作用を有する非糖質系甘味料と併用されることを特徴とする医薬組成物。
  3. ＧＬＰ−１分泌促進作用を有する非糖質系甘味料が、アセスルファムＫ、スクラロース、アスパルテーム及びステビアから選択される非糖質系甘味料である、請求項１又は２記載の医薬組成物。
  4. ＧＬＰ−１分泌促進作用を有する非糖質系甘味料が、アセスルファムＫ 及び スクラロースから選択される非糖質系甘味料である、請求項１又は２記載の医薬組成物。
  5. ＧＬＰ−１分泌促進作用を有する非糖質系甘味料が、アセスルファムＫである、請求項１又は２記載の医薬組成物。
  6. 肥満の治療又は予防のために使用されるものである請求項１〜５のいずれか１項記載の医薬組成物。
  7. 体重減少又は体脂肪減少のために使用されるものである請求項１〜５のいずれか１項記載の医薬組成物。
  8. 肥満の症状を有する患者における体重減少又は体脂肪減少のために使用されるものである請求項１〜５のいずれか１項記載の医薬組成物。
  9. ２型糖尿病および肥満の症状を有する患者における体重減少又は体脂肪減少のために使用されるものである請求項１〜５のいずれか１項記載の医薬組成物。
  10. ジペプチジルペプチダーゼ４阻害化合物とＧＬＰ−１分泌促進作用を有する非糖質系甘味料のほかに、少なくとも１種類の医薬的に許容される担体または賦形剤を含んで成る、請求項１〜９のいずれか１項記載の医薬組成物。
  11. 同時、別々、順次または連続的に使用するための組合せ製剤である、請求項１〜１０のいずれか１項記載の医薬組成物。
  12. 医薬の製造における、ジペプチジルペプチダーゼ４阻害化合物とＧＬＰ−１分泌促進作用を有する非糖質系甘味料との配合物の使用。
  13. 当該医薬が肥満の治療又は予防のための医薬である、請求項１２記載の使用。
  14. 当該医薬が体重減少又は体脂肪減少のための医薬である、請求項１２記載の使用。
  15. 当該医薬が肥満の症状を有する患者における体重減少又は体脂肪減少のための医薬である、請求項１２記載の使用。
  16. 当該医薬が２型糖尿病および肥満の症状を有する患者における体重減少又は体脂肪減少のための医薬である、請求項１２記載の使用。
  17. 有効成分として、ジペプチジルペプチダーゼ４阻害化合物とＧＬＰ−１分泌促進作用を有する非糖質系甘味料を、肥満の治療又は予防のために、同時、別々または連続的に使用するための指示書と共に含む、商品包装物。
JP2012174860A 2007-04-03 2012-08-07 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 Pending JP2012236849A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012174860A JP2012236849A (ja) 2007-04-03 2012-08-07 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90747107P 2007-04-03 2007-04-03
US60/907,471 2007-04-03
JP2007097079 2007-04-03
JP2007097079 2007-04-03
JP2012174860A JP2012236849A (ja) 2007-04-03 2012-08-07 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009507560A Division JP5616630B2 (ja) 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Publications (2)

Publication Number Publication Date
JP2012236849A JP2012236849A (ja) 2012-12-06
JP2012236849A5 true JP2012236849A5 (ja) 2013-06-13

Family

ID=39808393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009507560A Expired - Fee Related JP5616630B2 (ja) 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
JP2012174860A Pending JP2012236849A (ja) 2007-04-03 2012-08-07 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009507560A Expired - Fee Related JP5616630B2 (ja) 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Country Status (9)

Country Link
US (1) US8927504B2 (ja)
EP (1) EP2143443B1 (ja)
JP (2) JP5616630B2 (ja)
KR (2) KR20120030570A (ja)
CN (2) CN103330939A (ja)
AU (1) AU2008233548B2 (ja)
CA (1) CA2682736C (ja)
ES (1) ES2529149T3 (ja)
WO (1) WO2008120813A1 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US8927504B2 (en) * 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
WO2010039124A1 (en) * 2008-09-30 2010-04-08 Mitsubishi Tanabe Pharma Corporation Benzenesulfonic acid salt compounds
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP5721232B2 (ja) * 2009-12-04 2015-05-20 株式会社東洋新薬 グルカゴン様ペプチド−１分泌促進剤
JP5570244B2 (ja) * 2010-02-23 2014-08-13 株式会社ヤクルト本社 腸間膜脂肪低減剤
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5561639B2 (ja) * 2010-03-30 2014-07-30 静岡県公立大学法人 Ｇｐｒ４３陽性・腸内分泌細胞増加促進剤
JP6034781B2 (ja) * 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
BR112013009635A2 (pt) 2010-10-19 2016-07-12 Elcelyx Therapeutics Inc terapias à base de ligante de receptor quimiossensorial
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2015DN03795A (ja) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3194416A4 (en) * 2014-09-18 2018-02-14 The Trustees of Columbia University in the City of New York A neural substrate for sugar preference
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
JP6842072B2 (ja) * 2019-03-07 2021-03-17 物産フードサイエンス株式会社 エガセラ属細菌の菌数抑制剤
JP6765090B2 (ja) * 2019-05-14 2020-10-07 株式会社東洋新薬 黒生姜含有組成物
JPWO2021153718A1 (ja) * 2020-01-31 2021-08-05

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5982313A (ja) 1982-11-04 1984-05-12 Meiji Seika Kaisha Ltd 体内脂質減少剤
JPH0665080A (ja) 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JPH10290681A (ja) * 1997-04-18 1998-11-04 Suntory Ltd 抗肥満作用を有する飲食品
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
ES2311534T3 (es) 2000-08-10 2009-02-16 Mitsubishi Tanabe Pharma Corporation Derivados de prolina y su uso como farmacos.
US6849622B2 (en) * 2000-10-06 2005-02-01 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
US20040180925A1 (en) 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
US7026316B2 (en) 2001-03-27 2006-04-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20030031772A1 (en) * 2001-03-28 2003-02-13 Zehner Lee R. Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glyemic index
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
JP4300108B2 (ja) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
CA2450722A1 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20040259883A1 (en) 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
TW200401635A (en) 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
CA2496623C (en) 2002-08-29 2008-02-12 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2005170792A (ja) 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
PT1595866T (pt) 2003-01-31 2016-09-14 Sanwa Kagaku Kenkyusho Co Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
AU2004268024B2 (en) * 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1520486A1 (en) * 2003-09-30 2005-04-06 Tiense Suikerraffinaderij N.V. Composition for suppressing ghrelin and method for same
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
NZ548440A (en) 2004-02-05 2009-07-31 Kyorin Seiyaku Kk Bicycloester derivative inhibitng DPP-IV for treatment of diabetes or similar
KR20060129021A (ko) 2004-02-18 2006-12-14 교린 세이야꾸 가부시키 가이샤 비시클로아미드 유도체
EP1719757B1 (en) 2004-02-27 2013-10-09 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
EP2602259A3 (en) 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
WO2006090244A1 (en) 2005-02-22 2006-08-31 Glenmark Pharmaceuticals S.A. New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
JP2007001946A (ja) * 2005-06-24 2007-01-11 Ono Pharmaceut Co Ltd ピロリジン誘導体
US8927504B2 (en) * 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener

Similar Documents

Publication Publication Date Title
JP2012236849A5 (ja)
JP2014528474A5 (ja)
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
JP2010248252A5 (ja)
NI201100194A (es) Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral
MX2013002244A (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2013541583A5 (ja)
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
JP2007119497A5 (ja)
JP2011500589A5 (ja)
JP2014513121A5 (ja)
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
JP2017061488A5 (ja)
WO2009133470A3 (en) Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
MX2019014687A (es) Formulaciones farmaceuticas orales de remogliflozina.
RU2016144695A (ru) Комплекс танната ситаглиптина
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
WO2010142400A3 (de) Zusammensetzungen auf basis von chitosan-oligosacchariden
JP2015516451A5 (ja)
JP2016505628A5 (ja)